Moreover, GLP-1 agonist such as liraglutide activates cAMP that consequently inhibits the AKT signal pathway in pancreatic cancer cells (Zhao et al., 2014a; Zhao et al., 2014b). Here, AKT1 is linked to pancreatic neoplasm.